Intrinsic value of Abiomed - ABMD

Previous Close

$228.29

  Intrinsic Value

$66.94

stock screener

  Rating & Target

str. sell

-71%

Previous close

$228.29

 
Intrinsic value

$66.94

 
Up/down potential

-71%

 
Rating

str. sell

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of ABMD stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2017(a)
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  34.85
  29.10
  26.69
  24.52
  22.57
  20.81
  19.23
  17.81
  16.53
  15.37
  14.34
  13.40
  12.56
  11.81
  11.13
  10.51
  9.96
  9.47
  9.02
  8.62
  8.26
  7.93
  7.64
  7.37
  7.14
  6.92
  6.73
  6.56
  6.40
  6.26
  6.14
Revenue, $m
  445
  574
  728
  906
  1,111
  1,342
  1,600
  1,885
  2,197
  2,534
  2,898
  3,286
  3,699
  4,136
  4,596
  5,079
  5,585
  6,113
  6,665
  7,239
  7,837
  8,458
  9,104
  9,775
  10,473
  11,198
  11,952
  12,735
  13,551
  14,399
  15,282
Variable operating expenses, $m
 
  454
  574
  714
  874
  1,055
  1,258
  1,481
  1,725
  1,990
  2,275
  2,576
  2,900
  3,242
  3,603
  3,982
  4,379
  4,793
  5,225
  5,676
  6,144
  6,632
  7,138
  7,664
  8,211
  8,780
  9,370
  9,985
  10,624
  11,289
  11,982
Fixed operating expenses, $m
 
  3
  3
  3
  3
  3
  3
  4
  4
  4
  4
  4
  4
  4
  4
  4
  4
  5
  5
  5
  5
  5
  5
  5
  5
  6
  6
  6
  6
  6
  6
Total operating expenses, $m
  355
  457
  577
  717
  877
  1,058
  1,261
  1,485
  1,729
  1,994
  2,279
  2,580
  2,904
  3,246
  3,607
  3,986
  4,383
  4,798
  5,230
  5,681
  6,149
  6,637
  7,143
  7,669
  8,216
  8,786
  9,376
  9,991
  10,630
  11,295
  11,988
Operating income, $m
  90
  118
  151
  189
  233
  283
  339
  400
  468
  540
  619
  706
  795
  889
  988
  1,093
  1,202
  1,316
  1,435
  1,559
  1,688
  1,822
  1,961
  2,106
  2,256
  2,413
  2,575
  2,745
  2,920
  3,104
  3,294
EBITDA, $m
  96
  126
  161
  201
  247
  299
  357
  421
  491
  567
  649
  736
  829
  927
  1,031
  1,139
  1,253
  1,372
  1,496
  1,625
  1,760
  1,900
  2,045
  2,196
  2,353
  2,516
  2,686
  2,862
  3,046
  3,237
  3,435
Interest expense (income), $m
  0
  1
  2
  3
  4
  6
  7
  9
  12
  14
  16
  19
  22
  25
  29
  32
  36
  40
  44
  48
  52
  57
  62
  67
  72
  77
  83
  88
  94
  100
  107
Earnings before tax, $m
  91
  117
  149
  187
  229
  278
  332
  391
  456
  527
  602
  687
  773
  864
  960
  1,060
  1,166
  1,276
  1,391
  1,511
  1,635
  1,765
  1,899
  2,039
  2,185
  2,336
  2,493
  2,656
  2,826
  3,003
  3,187
Tax expense, $m
  39
  32
  40
  50
  62
  75
  90
  106
  123
  142
  163
  185
  209
  233
  259
  286
  315
  345
  376
  408
  442
  476
  513
  551
  590
  631
  673
  717
  763
  811
  861
Net income, $m
  52
  86
  109
  136
  168
  203
  242
  286
  333
  384
  440
  501
  564
  630
  701
  774
  851
  931
  1,015
  1,103
  1,194
  1,288
  1,387
  1,489
  1,595
  1,705
  1,820
  1,939
  2,063
  2,192
  2,327

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  230
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  550
  413
  523
  652
  799
  965
  1,150
  1,355
  1,579
  1,822
  2,083
  2,362
  2,659
  2,973
  3,304
  3,651
  4,015
  4,395
  4,791
  5,204
  5,634
  6,081
  6,545
  7,028
  7,529
  8,050
  8,592
  9,155
  9,742
  10,352
  10,987
Adjusted assets (=assets-cash), $m
  320
  413
  523
  652
  799
  965
  1,150
  1,355
  1,579
  1,822
  2,083
  2,362
  2,659
  2,973
  3,304
  3,651
  4,015
  4,395
  4,791
  5,204
  5,634
  6,081
  6,545
  7,028
  7,529
  8,050
  8,592
  9,155
  9,742
  10,352
  10,987
Revenue / Adjusted assets
  1.391
  1.390
  1.392
  1.390
  1.390
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
  1.391
Average production assets, $m
  70
  90
  114
  142
  174
  211
  251
  296
  345
  398
  455
  516
  581
  649
  722
  797
  877
  960
  1,046
  1,137
  1,230
  1,328
  1,429
  1,535
  1,644
  1,758
  1,876
  1,999
  2,127
  2,261
  2,399
Working capital, $m
  257
  36
  46
  57
  70
  85
  101
  119
  138
  160
  183
  207
  233
  261
  290
  320
  352
  385
  420
  456
  494
  533
  574
  616
  660
  705
  753
  802
  854
  907
  963
Total debt, $m
  16
  43
  77
  115
  160
  210
  267
  329
  396
  470
  549
  634
  724
  819
  919
  1,024
  1,135
  1,250
  1,370
  1,495
  1,625
  1,760
  1,901
  2,047
  2,199
  2,357
  2,521
  2,692
  2,870
  3,055
  3,247
Total liabilities, $m
  98
  125
  159
  197
  242
  292
  349
  411
  478
  552
  631
  716
  806
  901
  1,001
  1,106
  1,217
  1,332
  1,452
  1,577
  1,707
  1,842
  1,983
  2,129
  2,281
  2,439
  2,603
  2,774
  2,952
  3,137
  3,329
Total equity, $m
  452
  288
  365
  454
  557
  672
  802
  945
  1,101
  1,270
  1,452
  1,647
  1,853
  2,072
  2,303
  2,545
  2,798
  3,063
  3,340
  3,627
  3,927
  4,238
  4,562
  4,898
  5,248
  5,611
  5,989
  6,381
  6,790
  7,215
  7,658
Total liabilities and equity, $m
  550
  413
  524
  651
  799
  964
  1,151
  1,356
  1,579
  1,822
  2,083
  2,363
  2,659
  2,973
  3,304
  3,651
  4,015
  4,395
  4,792
  5,204
  5,634
  6,080
  6,545
  7,027
  7,529
  8,050
  8,592
  9,155
  9,742
  10,352
  10,987
Debt-to-equity ratio
  0.035
  0.150
  0.210
  0.250
  0.290
  0.310
  0.330
  0.350
  0.360
  0.370
  0.380
  0.380
  0.390
  0.400
  0.400
  0.400
  0.410
  0.410
  0.410
  0.410
  0.410
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
  0.420
Adjusted equity ratio
  0.694
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697
  0.697

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  52
  86
  109
  136
  168
  203
  242
  286
  333
  384
  440
  501
  564
  630
  701
  774
  851
  931
  1,015
  1,103
  1,194
  1,288
  1,387
  1,489
  1,595
  1,705
  1,820
  1,939
  2,063
  2,192
  2,327
Depreciation, amort., depletion, $m
  6
  8
  10
  11
  13
  15
  18
  21
  23
  27
  30
  30
  34
  38
  42
  47
  52
  56
  62
  67
  72
  78
  84
  90
  97
  103
  110
  118
  125
  133
  141
Funds from operations, $m
  120
  94
  119
  148
  181
  218
  260
  306
  356
  411
  470
  532
  598
  669
  743
  821
  903
  988
  1,077
  1,170
  1,266
  1,366
  1,471
  1,579
  1,692
  1,809
  1,930
  2,057
  2,188
  2,325
  2,468
Change in working capital, $m
  5
  8
  10
  11
  13
  15
  16
  18
  20
  21
  23
  24
  26
  28
  29
  30
  32
  33
  35
  36
  38
  39
  41
  42
  44
  46
  47
  49
  51
  53
  56
Cash from operations, $m
  115
  86
  109
  137
  168
  204
  244
  288
  337
  390
  447
  507
  572
  641
  714
  791
  871
  955
  1,042
  1,133
  1,228
  1,327
  1,430
  1,537
  1,648
  1,763
  1,883
  2,007
  2,137
  2,272
  2,412
Maintenance CAPEX, $m
  0
  -4
  -5
  -7
  -8
  -10
  -12
  -15
  -17
  -20
  -23
  -27
  -30
  -34
  -38
  -42
  -47
  -52
  -56
  -62
  -67
  -72
  -78
  -84
  -90
  -97
  -103
  -110
  -118
  -125
  -133
New CAPEX, $m
  -50
  -20
  -24
  -28
  -32
  -36
  -41
  -45
  -49
  -53
  -57
  -61
  -65
  -69
  -72
  -76
  -79
  -83
  -87
  -90
  -94
  -98
  -101
  -105
  -110
  -114
  -118
  -123
  -128
  -133
  -139
Cash from investing activities, $m
  -126
  -24
  -29
  -35
  -40
  -46
  -53
  -60
  -66
  -73
  -80
  -88
  -95
  -103
  -110
  -118
  -126
  -135
  -143
  -152
  -161
  -170
  -179
  -189
  -200
  -211
  -221
  -233
  -246
  -258
  -272
Free cash flow, $m
  -11
  62
  80
  102
  127
  157
  191
  229
  270
  316
  366
  419
  477
  538
  604
  672
  744
  820
  899
  982
  1,068
  1,157
  1,250
  1,347
  1,448
  1,552
  1,661
  1,774
  1,891
  2,013
  2,141
Issuance/(repayment) of debt, $m
  0
  28
  33
  39
  45
  50
  56
  62
  68
  74
  79
  85
  90
  95
  100
  105
  110
  115
  120
  125
  130
  135
  141
  146
  152
  158
  164
  171
  178
  185
  192
Issuance/(repurchase) of shares, $m
  12
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  4
  28
  33
  39
  45
  50
  56
  62
  68
  74
  79
  85
  90
  95
  100
  105
  110
  115
  120
  125
  130
  135
  141
  146
  152
  158
  164
  171
  178
  185
  192
Total cash flow (excl. dividends), $m
  -9
  90
  113
  141
  172
  207
  247
  291
  338
  390
  445
  504
  567
  634
  704
  777
  855
  935
  1,019
  1,107
  1,198
  1,293
  1,391
  1,493
  1,600
  1,710
  1,825
  1,945
  2,069
  2,198
  2,333
Retained Cash Flow (-), $m
  -83
  -65
  -77
  -89
  -102
  -116
  -129
  -143
  -156
  -169
  -182
  -195
  -207
  -219
  -231
  -242
  -254
  -265
  -276
  -288
  -299
  -311
  -324
  -336
  -350
  -363
  -378
  -393
  -408
  -425
  -443
Prev. year cash balance distribution, $m
 
  229
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  254
  36
  51
  70
  92
  118
  148
  182
  221
  263
  309
  360
  415
  473
  535
  601
  670
  743
  819
  898
  981
  1,067
  1,157
  1,250
  1,347
  1,448
  1,552
  1,660
  1,773
  1,890
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  243
  33
  45
  57
  71
  85
  100
  114
  127
  138
  147
  154
  158
  159
  157
  153
  146
  137
  126
  114
  101
  89
  76
  64
  52
  42
  33
  26
  19
  14
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

FINANCIAL RATIOS  of  Abiomed (ABMD)

Valuation Ratios
P/E Ratio 191.7
Price to Sales 22.4
Price to Book 22.1
Price to Tangible Book
Price to Cash Flow 86.7
Price to Free Cash Flow 153.4
Growth Rates
Sales Growth Rate 34.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 212.5%
Cap. Spend. - 3 Yr. Gr. Rate 75.5%
Financial Strength
Quick Ratio 230
Current Ratio 0
LT Debt to Equity 3.3%
Total Debt to Equity 3.5%
Interest Coverage 0
Management Effectiveness
Return On Assets 10.7%
Ret/ On Assets - 3 Yr. Avg. 20.9%
Return On Total Capital 12.4%
Ret/ On T. Cap. - 3 Yr. Avg. 24.5%
Return On Equity 12.7%
Return On Equity - 3 Yr. Avg. 24.6%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 84.3%
Gross Margin - 3 Yr. Avg. 83.8%
EBITDA Margin 21.8%
EBITDA Margin - 3 Yr. Avg. 18.9%
Operating Margin 20.2%
Oper. Margin - 3 Yr. Avg. 17.5%
Pre-Tax Margin 20.4%
Pre-Tax Margin - 3 Yr. Avg. 17.7%
Net Profit Margin 11.7%
Net Profit Margin - 3 Yr. Avg. 24.3%
Effective Tax Rate 42.9%
Eff/ Tax Rate - 3 Yr. Avg. -69.3%
Payout Ratio 0%

ABMD stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the ABMD stock intrinsic value calculation we used $445 million for the last fiscal year's total revenue generated by Abiomed. The default revenue input number comes from 2017 income statement of Abiomed. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our ABMD stock valuation model: a) initial revenue growth rate of 29.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for ABMD is calculated based on our internal credit rating of Abiomed, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Abiomed.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of ABMD stock the variable cost ratio is equal to 79.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $3 million in the base year in the intrinsic value calculation for ABMD stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Abiomed.

Corporate tax rate of 27% is the nominal tax rate for Abiomed. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the ABMD stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for ABMD are equal to 15.7%.

Life of production assets of 17 years is the average useful life of capital assets used in Abiomed operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for ABMD is equal to 6.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $452 million for Abiomed - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 44.982 million for Abiomed is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Abiomed at the current share price and the inputted number of shares is $10.3 billion.

RELATED COMPANIES Price Int.Val. Rating
TFX Teleflex 276.42 84.85  str.sell
ATRC AtriCure 17.60 0.45  str.sell
BSX Boston Scienti 27.65 10.23  str.sell

COMPANY NEWS

▶ Breakout Watch: 97 A+ Funds Have Positions In This IBD 50 Stock   [Jan-19-18 04:07PM  Investor's Business Daily]
▶ 3 Healthcare Stocks to Buy for 2018   [Jan-17-18 08:34AM  Motley Fool]
▶ Stocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day Support   [Jan-16-18 03:08PM  Investor's Business Daily]
▶ Abiomed At Top End Of Buy Zone With Earnings Due   [Jan-10-18 03:00AM  Investor's Business Daily]
▶ New Strong Buy Stocks for January 4th   [Jan-04-18 10:00AM  Zacks]
▶ ETFs with exposure to ABIOMED, Inc. : December 18, 2017   [Dec-18-17 02:17PM  Capital Cube]
▶ 10 Best of the Best Stocks to Buy for 2018   [Dec-08-17 02:09PM  InvestorPlace]
▶ ETFs with exposure to ABIOMED, Inc. : December 5, 2017   [Dec-05-17 12:15PM  Capital Cube]
▶ ETFs with exposure to ABIOMED, Inc. : November 24, 2017   [Nov-24-17 10:20AM  Capital Cube]
▶ ETFs with exposure to ABIOMED, Inc. : November 13, 2017   [Nov-13-17 11:31AM  Capital Cube]
▶ 7 Tech Stocks to Buy That Sport Amazon-Like Growth   [Nov-10-17 12:51PM  InvestorPlace]
▶ ETFs with exposure to ABIOMED, Inc. : November 1, 2017   [Nov-01-17 11:45AM  Capital Cube]
▶ Company News For Oct 27, 2017   [Oct-27-17 10:17AM  Zacks]
▶ Abiomed, Inc's Revenue and Profits Soar Yet Again   [Oct-26-17 03:50PM  Motley Fool]
▶ Abiomed beats Street 2Q forecasts   [07:35AM  Associated Press]
▶ 3 Stocks That Could Be Life-Changers   [Oct-06-17 08:15PM  Motley Fool]
▶ Stocks With Rising Relative Strength: Penumbra   [03:00AM  Investor's Business Daily]
▶ 3 Stocks That Could Soar More Than Priceline   [Sep-19-17 09:45AM  Motley Fool]
▶ Abiomed searches for new CFO after Tomsicek resigns   [Aug-28-17 04:27PM  MarketWatch]
▶ ETFs with exposure to ABIOMED, Inc. : August 15, 2017   [Aug-15-17 03:07PM  Capital Cube]
▶ Abiomed beats Street 1Q forecasts   [01:24AM  Associated Press]
Financial statements of ABMD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.